Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload

Advances in Therapy

Volumn 25, Issue 8, 2008, Pages 725-742

  Payne, Krista A ^a   Rofail, Diana ^b   Baladi, Jean François ^c   Viala, Muriel ^b   Abetz, Linda ^b   Desrosiers, Marie Pierre ^a   Lordan, Noreen ^a   Ishak, Khajak ^a   Proskorovsky, Irina ^a  

^a UNITED BIOSOURCE CORPORATION   (Canada)

^b MAPI VALUES   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Clinical effectiveness; Economic burden; Health related quality of life; ICT; Iron overload

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CHELATION THERAPY; CHILD; COST; ECONOMICS; FEMALE; HUMAN; IRON OVERLOAD; MALE; QUALITY OF LIFE;

ADOLESCENT; ADULT; CHELATION THERAPY; CHILD; COSTS AND COST ANALYSIS; DEFEROXAMINE; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PYRIDONES; QUALITY OF LIFE; YOUNG ADULT;

EID: 58749094452     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0085-z     Document Type: Review

References (46)

1. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761. (Pubitemid 27121266)
2. Harvard Medical School. Effects of iron overload: hemochromatosis, tranfusional iron overload. 2006. Available at: http://sickle.bwh.harvard.edu/ index.html. Accessed June 2008.
3. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26-36. (Pubitemid 26071428)
4. Vidler V. Compliance with iron chelation therapy in beta thalassaemia. Paediatr Nurs. 1998;10:17-18.
5. Rebulla P. Transfusion reactions in thalassemia. A survey from the Cooleycare programme. The Cooleycare Cooperative Group. Haematologica. 1990;75(suppl 5): 122-127. (Pubitemid 20359678)
6. Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol. 2001;38:360-366. (Pubitemid 32995605)
7. Alymara V, Bourantas D, Chaidos A, et al. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Hematol J. 2004;5:475-479. (Pubitemid 40045280)
8. Shumaker SA, Berzon RA. The International Assessment of HRQL. Teory, Translations, Measurement and Analysis. Oxford: Rapid Communications; 1995.
9. Abetz L, Baladi JF, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes. 2006;4:73.
10. Hasan SP, Hashmi S, Alhassen M, et al. Depression in sickle cell disease. J Natl Med Assoc. 2003;95:533-537. (Pubitemid 37107831)
11. Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441-2452. (Pubitemid 34525729)
12. Olivieri N, Brittenham GM, McLaren CE, et al. Long-term safety and Effectivness of iron chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339:417-423. (Pubitemid 28377682)
13. Caro JJ, Huybrechts K, Green TC. Estimates of the Effect on hepatic iron of oral deferiprone compared to subcutaneous desferrioxamine for treatment of iron overload in thalassaemia major: a systematic review. BMC Blood Disord. 2002;2:4.
14. Payne KA, Desrosiers M P, Caro JJ, et al. Clinical and economic burden of infused iron chelation therapy (ICT) in the United States. Transfusion. 2007;47:1820-1829. (Pubitemid 47438548)
15. Serjeant GR. Sickle-cell disease. Lancet. 1997;350:725-730. (Pubitemid 127739268)
16. Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with inEffective hematopoiesis. N Engl J Med. 2005;352:536-538.
17. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
18. Rofail D, Abetz L, Viala M, et al. Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed questionnaire. Value Health. 2008; Jul 11. Epub ahead of print.
19. Brazier J, Usherwood T, Harper R, Tomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol. 1998;51:1115-1128. (Pubitemid 28527167)
20. Gold MR, Siegel JE, Russell LB, Weistein MC. Cost Effectiveness in Health and Medicine. Oxford: Oxford University Press; 1996.
21. Zeuner D, Ades A, Karnon J, et al. Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. NHS Health Technol Assess Prog. 1999;3:1-186.
22. Wayne A, Schoenike S, Pegelow C, et al. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood. 2000;96:2367-2369.
23. Karnon J, Zeuner D, Brown J, et al. Lifetime treatment cost of beta-thalassemia major. Clin Lab Haem. 1992;21:377-385.
24. Ginsberg G, Tulchinsky T, Filon D, et al. Cost-beneft analysis of a national thalassemia prevention programme in Israel. J Med Screen. 1998;5:120-126. (Pubitemid 28442992)
25. Jenkinson C, Stewart-Brown S, Petersen S. Assessment and Evaluation of the SF36 Version II. Health Services Research Unit: University of Oxford; 2006. Available at: www.hsru.ox.ac.uk/sf36v2.htm. Accessed 9 February 2006.
26. Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68:2801-2808. (Pubitemid 43251026)
27. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2001;21:271-292.
28. Landgraf JM, Abetz L, Ware JE. The Child Health Questionnaire (CHQ): a User's Manual. 2nd ed. Boston, MA: The Health Institute; 1996.
29. Medi-Scot web site. Available at: www.medi-scot.co.uk. Accessed 18 September 2006.
30. Medicines and Healthcare Products Regulatory Agency. Market survey. Non-electrically powered dispoable infusion devices. Report 05055. September 2005. Available at: www.pasa.nhs.uk/evaluation/docs/general-medical/Report-05055 pdf. Accessed 23 October 2006.
31. Williams Medical Supplies. Available at: www wmsplc.co.uk. Accessed 18 September 2006.
32. Modell B. Guidelines for the control of haemoglobin disorders. Report of the Sixth Annual Meeting of the WHO Working Group on Haemoglobinopathies, Cagliari, Sardinia, 8-9 April 1989. Geneva: World Health Organization; 2004.
33. Chan GC, Ng DM, Fong DY, et al. Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model. Am J Hematol. 2004;76:398-404. (Pubitemid 38988629)
34. Curtis L, Netten A. Unit Costs of Health and Social Care 2005. The University of Kent, Personal Social Services Research Unit 202.
35. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta thalassemia. N Engl J Med. 1994;331:574-578. (Pubitemid 24265699)
36. Telfer PTT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971-977.
37. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187-1193. (Pubitemid 39390442)
38. Talassemia International Federation web site. Guidelines for Clinical Management of Talassemia. 2000. Available at: www. thalassaemia.org.cy/MyData/ Books/Clinical-%20Management-Talassaemia. pdf. Accessed June 2008.
39. Arboretti R, Tognoni G, Alberti D. Italian Collaborative Group on Talassarmia. Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol. 2001;56:915-922. (Pubitemid 33788570)
40. Taher A, Sheikh-Taha M, Koussa S, et al. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol. 2001;67:30-34. (Pubitemid 32771383)
41. Caro JJ, Ward A, Green TC, et al. Impact of thalassemia major on patients and their families. Acta Haematol. 2002;107: 150-157. (Pubitemid 34455079)
42. Ward A, Caro JJ, Green TC, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol. 2002;2:3.
43. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood. 2004;104:34-39. (Pubitemid 38879833)
44. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specifc health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43:1478-1487. (Pubitemid 30452465)
45. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important diferences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999;15: 141-155. (Pubitemid 29093257)
46. Williams JJ, Calnan M. Convergence and divergence: assessing criteria of consumer satisfaction across general practice, dental, and hospital care settings. Soc Sci Med. 1991;33:707-716.